



Library and Information Service
Royal College of Psychiatrists
17 Belgrave Square
London SW1X 8PG
☎ 0171-235-2351-X138

EDITORIALS

471 The contribution of Michael Rutter

I. Kolvin

476 New drugs for Alzheimer's disease

A. Burns, E. Russell and S. Page

REVIEW ARTICLE

480 Psychosocial adversity and child psychopathology

M. L. Rutter

INTERVIEW

494 Talking with Michael Rutter

I. Kolvin

PAPERS

500 Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up

N. Tarrrier, A. Wittkowski, C. Kinney, E. McCarthy, J. Morris and L. Humphreys

505 Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia

C. Barrowclough, N. Tarrrier, S. Lewis, W. Sellwood, J. Mainwaring, J. Quinn and C. Hamlin

512 Reduction of the parahippocampal gyrus and the hippocampus in patients with chronic schizophrenia

K. Razi, K. P. Greene, M. Sakuma, S. Ge, M. Kushner and L. E. DeLisi

520 Fever and acute brief psychosis in urban and rural settings in north India

P. Y. Collins, V. K. Varma, N. N. Wig, R. Mojtabai, R. Day and E. Sussner

525 Brain mechanisms associated with depressive relapse and associated cognitive impairment following acute tryptophan depletion

K. A. Smith, J. S. Morris, K. J. Friston, P. J. Cowen and R. J. Dolan

530 Aetiological risk factors for personality disorders

J. W. Coid

539 Cognitive disability and direct care costs for elderly people

S. Kavanagh and M. Knapp

PRELIMINARY REPORT

547 People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study

A. Hodges, M. Byrne, E. Grant and E. Johnstone

554 Invited commentaries on: People at risk of schizophrenia

A. Farmer; K. S. Kendler; A. Jablensky; T. J. Crow; author's response by E. Johnstone

COLUMNS

558 Correspondence

565 One hundred years ago

567 Book reviews

568 Contents of *The American Journal of Psychiatry*

Their doctor knew that their symptoms were similar



Symptoms: Low mood, suicidal thoughts
Diagnosis: **Depression**

Symptoms: Palpitations, intense anxiety
Diagnosis: **Panic disorder**



Symptoms: Sleep disturbance, hopelessness
Diagnosis: **Depression**

Depression and panic disorder are seen across all age groups in both sexes. From the doctor's viewpoint, overlapping symptoms can make them appear similar. For the patients, the same effective treatment can make a real difference to their quality of life.

Cipramil combines proven efficacy with an established safety and tolerability profile, which makes it a logical first choice for patients suffering from depression or panic disorder. For effective relief from depression and panic disorder, prescribe Cipramil - the most selective SSRI - and make a real difference to your patients.

Cipramil ▼
citalopram
*make a difference in depression
and panic disorder*

They just know that Cipramil makes a real difference



Abbreviated prescribing information. Presentation: 'Cipramil' tablets 10 mg; PL 0458/0057, each containing 10 mg of citalopram as the hydrobromide. 28 (OP) 10 mg tablets £10.09. 'Cipramil' tablets 20 mg; PL 0458/0058, each containing 20 mg of citalopram as the hydrobromide. 28 (OP) 20 mg tablets £16.79. 'Cipramil' tablets 40 mg; PL 0458/0059, each containing 40 mg of citalopram as the hydrobromide. 28 (OP) 40 mg tablets £28.38. **Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/ recurrence. Treatment of panic disorder, with or without agoraphobia. **Dosage:** *Treating depression:* Adults: 20 mg a day. Depending upon individual patient response, this may be increased in 20 mg increments to a maximum of 60 mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. Treatment for at least 6 months is usually necessary to provide adequate maintenance against the potential for relapse. *Treating panic disorder:* 10 mg daily for the first week, increasing to 20 mg daily. Depending upon individual patient response, dosage may be further increased to a maximum of 60 mg daily. Depending upon individual patient response, it may be necessary to continue treatment for several months. **Elderly:** 20 mg a day increasing to a maximum of 40 mg dependent upon individual patient response. **Children:** Not recommended. **Reduced hepatic/renal function:** Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. Use a low starting dose for panic disorder, to reduce the likelihood of an initial anxiogenic effect (experienced by some patients) when starting pharmacotherapy. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and tryptophan with caution. Routine monitoring of lithium levels need not be adjusted **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. With citalopram, adverse effects are in general mild and transient. When they occur, they are most prominent during the first two weeks of treatment and usually attenuate as the depressive state improves. Withdrawal symptoms have been reported with SSRIs. Abrupt withdrawal of citalopram should be avoided. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request Product licence holder: Lundbeck Ltd., Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a Registered Trade Mark. © 1998 Lundbeck Ltd. Date of preparation: January 1999 1298/CIP/501/056



EDITOR Greg Wilkinson LIVERPOOL

EDITORIAL BOARD

DEPUTY EDITOR

Alan Kerr
NEWCASTLE UPON TYNE

ASSOCIATE EDITORS

Sidney Crown
LONDON

Julian Leff
LONDON

Sir Martin Roth, FRS
CAMBRIDGE

Sir Michael Rutter, FRS
LONDON

Peter Tyrer
LONDON

EDITORIAL ADVISERS

Howard Croft
OXFORD

Tony Johnson
CAMBRIDGE

Kathleen Jones
YORK

Martin Knapp
LONDON

Herschel Prins
LEICESTER

John Wing
LONDON

Sir John Wood
SHEFFIELD

ASSISTANT EDITORS

Louis Appleby
MANCHESTER

Alistair Burns
MANCHESTER

Patricia Casey
DUBLIN

John Cookson
LONDON

Tom Fahy
LONDON

Anne Farmer
CARDIFF

Michael Farrell
LONDON

Nicol Ferrier
NEWCASTLE UPON TYNE

Simon Gowers
CHESTER

Richard Harrington
MANCHESTER

Sheila Hollins
LONDON

Jeremy Holmes
BARNSTAPLE

Michael King
LONDON

Michael Kopelman
LONDON

Alan Lee
NOTTINGHAM

Glyn Lewis
CARDIFF

Shôn Lewis
MANCHESTER

Robin McCreadie
DUMFRIES

Ian McKeith
NEWCASTLE UPON TYNE

J. Spencer Madden
UPTON-BY-CHESTER

David Owens
LEEDS

Ian Pullen
MELROSE

Henry Rollin
LONDON

Jan Scott
GLASGOW

Andrew Sims
LEEDS

George Stein
LONDON

CORRESPONDING EDITORS

Andrew Cheng
TAIWAN

Kenneth Kendler
USA

Arthur Kleinman
USA

Paul Mullen
AUSTRALIA

Michele Tansella
ITALY

J. L. Vázquez-Barquero
SPAIN

STATISTICAL ADVISER

Pak Sham
LONDON

STAFF

PUBLICATIONS MANAGER
Dave Jago

MARKETING MANAGER
Lucy Alexander

SCIENTIFIC EDITOR
Andrew Morris

ASSISTANT SCIENTIFIC EDITORS
Bryony Stuart

Zoë Stagg

EDITORIAL ASSISTANTS
Eloise Glover

Sue Thakor

MARKETING OFFICER
Emily Falconer

Subscriptions

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1999 (12 issues post free) are as follows:

	INSTITUTIONS	INDIVIDUALS
Europe (& UK)	£185	£157
US	\$375	\$270
Elsewhere	£220	£170

Full airmail is £36/
US\$64 extra.

Single copies of the
journal are £19, \$30
(post free)

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Payment should be made out to the British Journal of Psychiatry.

Back issues

Back issues published before 1996 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

Advertising

Correspondence and copy should be addressed to Stephen H. P. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SM1 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

US Mailing Information

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$375. Second class postage paid at Rathway, NJ. Postmaster send address corrections to the British Journal of Psychiatry, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

™The paper used in this publication meets the minimum requirements of the American National Standard for Information Sciences – Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Typeset by Dobbie Typesetting Ltd, Tavistock.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

Past Editors

Eliot Slater	1961–72	John L. Crammer	1978–83
Edward H. Hare	1973–77	Hugh L. Freeman	1984–93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963.

©1999 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. Manuscripts for publication should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG. Queries, letters to the Editor and book reviews may also be sent electronically to sthakor@rcpsych.ac.uk.

Instructions to authors

Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below. Copies are also available from the Journal Office.

Information about the College's publications is available on the World Wide Web at <http://www.rcpsych.ac.uk>.

**BBR
MEDICAL
EDUCATION**

Intensive weekend courses

**MRCPsychiatry Parts I & II
Written and Clinical skills courses**

MRCPsychiatry Part I written 11-12 September

MRCPsychiatry Part II written 11-12 September

Critical Appraisal - Four hour course
10 September 1999

MRCPsychiatry clinical 6-7 November

BBR Courses are
Stimulating, entertaining and successful.

Telephone or Fax 0181-959-7562
33 Flower Lane, Mill Hill, London NW7

**New Brief Pulse ECT with Computer-Assisted
Easy Seizure Monitoring**



Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in the U.K. by: DANTEC Electronics, Ltd. Garonor Way Royal Portbury Bristol BS20 9XE TEL (44) 1275-375333 FAX (44) 1275-375336	Distributed in Australia by: SONORAY Pty. Ltd. 32 Miamba Ave. Carlingford NSW 2118 TEL (61) 29-871-0804 FAX (61) 29-779-2110	Distributed in New Zealand by: MEDIC Healthcare Ltd. 20 Peterkin St. Wingate Lower Hutt TEL (64) 4-577-0000 FAX (64) 4-577-2000
Distributed in Ireland by: BRENNAN & CO. Dublin TEL (353) 1-295-2501 FAX (353) 1-295-2333	Distributed in India by: HOSPIMEDICA Pvt. Ltd. 58/10, 11d floor, Ashok Nagar New Delhi 110 018 TEL (91) 11-540-0984 FAX (91) 11-549-2977	Distributed in South Africa by: DELTA SURGICAL Craighall TEL (27) 11-792-6120 FAX (27) 11-792-6926

ASK ABOUT THE NEW 4-CHANNEL THYMATRON SYSTEM IV™
SOMATICS, INC., 910 Sherwood Drive # 17, Lake Bluff, IL, 60044, U.S.A.
Fax: (847) 234-6763; Tel: (847) 234-6761

PSYCHIATRISTS

- Positions across the UK, Middle East & USA
- All Grades
- Quality locum positions
- Long & short term
- Excellent on-call
- Top rates paid

Apply on-line:
www.directmedical.co.uk

Call now for further details

Tel: 01792 472 525

Fax: 01792 472 535

e-mail: info@directmedical.co.uk

The Psychiatrists' Choice.

Direct Medical



Appointments



HARLEY STREET

OCCASIONAL AND SESSIONAL ROOMS

Open Monday-Friday, 9.00am-9.00pm
Saturday and Sunday, 9.00am-5.30pm
Early mornings by arrangement

**FLEXIBLE, COST-EFFECTIVE
CONSULTING OPTIONS
PERSONALISED TELEPHONE ANSWERING
AND FULL ADMINISTRATIVE SUPPORT**

TELEPHONE 0171 467 8301



Expert Speakers include:

- **Professor Thomas Barnes** – London. Introduction and Welcome.
- **Dr David Cunningham-Owens** – Edinburgh. The clinical impact of the new anti-psychotic agents.
- **Dr Stephen Cooper** – Belfast. Review of adjunctive therapies for schizophrenia and TD.
- **Professor John Waddington** – Dublin. Understanding the aetiology of TD and hope for the future.

Invitation

RCP ANNUAL MEETING

Current Perspectives in Tardive Dyskinesia Satellite Symposium

- ▶ Tardive Dyskinesia is a debilitating side effect of anti-psychotic agents, and the symptoms are thought to be an underlying cause of the stigma associated with schizophrenia.
- ▶ Is there a component of TD which is intrinsic to the pathophysiology of schizophrenia?
- ▶ With the introduction of the new atypical anti-psychotic drugs, will the symptoms of TD be reduced? What is the medical opinion on the current use of this new therapy and its clinical data? What is the view on the treatment options for TD, which are currently under development?
- ▶ There is a clear need to treat the symptoms of TD to ensure a high level of compliance amongst schizophrenic patients thus decreasing the prevalence of the disease and improving both patients and carers quality of life.

A series of presentations + discussion forum

AT: **ICC, Birmingham**

ON: **Monday 28th June 1999**

TIME: **6.45pm – 8.30pm** followed by drinks and supper



PARTNERSHIP IN
RESEARCH
INFORMATION
SUPPORT
EDUCATION

For further information and bookings please contact: Symposium Organiser, Peregrine Park, Gomm Road, High Wycombe, HP13 7DL Tel: 01494 448588 Fax: 01494 528437 email lisa.burridge@counsellor.holmes-marchant.com

Supported by an educational grant from SHS International as a service to medicine

**To register for the Satellite Symposium, please fax back this slip with your details to:
01494 528437**

Name: _____

Address: _____

Postcode: _____



LOCUMS
(UK) LIMITED
The National Medical Recruitment Company

PSYCHIATRISTS

**England – Scotland – Wales
all areas**

Varied assignments
Weekly Payments
Expenses
Professional and Friendly Service
Also GP Locum Specialists

Call us today

Locums (UK)

Tel: 01489 788772 Fax: 01489 788771
email: doctors@locums.co.uk

P

THE PORTMAN CLINIC
**Diploma in Forensic
Psychotherapeutic Studies**
Awarded by University College, London

This Diploma course is aimed at all professionals working with offenders in hospitals, special hospitals, secure units, prisons, probation offices, the courts and the community. It provides special experience in work with offenders but does not constitute a general psychotherapy training.

The course aims to increase candidates' understanding of the psychodynamic considerations underlying offending behaviour in a criminal context so that those graduating from the course are better able to:

- integrate psychodynamic theory and practice in the forensic setting
- gain forensic clinical experience informed by working with a forensic patient
- recognise the personal and institutional impact of working with the forensic patient
- recognise the impact of offending and abusive experience on patients and take a more reflective approach to work in a forensic setting
- understand professional conflicts and improve interagency collaboration.

The course structure includes small group supervision of psychotherapy with a forensic patient: interdisciplinary discussions of psychotherapeutic practice in a variety of work settings: reading and lectures on theoretical and clinical topics; personal experience in psychoanalytic psychotherapy.

Time commitment: A 2 year course which runs 1 day a week in term time. (The academic year is 30 weeks).

Fee: £1810 per annum

Further information available from: The Portman Clinic, 8 Fitzjohns Avenue, London, NW3 5NA. Tel: 0171 794 8262

Email: Portman@tavi-port.org Please quote ref: P2

We are striving towards Equal Opportunities and operate a No-Smoking Policy.

NB **MEDICAL EDUCATION**

MRCPSYCH PART I LONDON

Intensive exam-orientated weekend courses

- Theory for *new syllabus*.
- Technique and tactics.
- Over 2000 relevant MCQ's.
- Practice MCQ exams.
- HM67(27) approved for study leave.

London 28 and 29 August, 4 and 5 September
(4 day course).

Details: NB Medical Education, PO Box 767,
OXFORD OX1 1XD. Tel/fax. 01865 842206.

RESEARCH FELLOWSHIP

National Institute of Mental Health National Institutes of Health Bethesda, Maryland

Starting July 2000, there is a 2–5 year post-doctoral Research Fellowship in the Child Psychiatry Branch, National Institute of Mental Health, involving clinical, pharmacologic genetic, and neuroimaging studies of childhood onset schizophrenia. Core training curriculum and other courses provided on an individual basis. Salary will be based on education and experience. Educational Commission for Foreign Medical Graduates (ECFMG) certification is required. Training in Child Psychiatry is desirable.

Please send resume, two letters of reference, and proof of medical degree (English translation required unless in Latin) to:

**Dr Judith L. Rapoport, Chief, Child Psychiatry
Branch, National Institute of Mental Health,
Building 10, Room 3N202, 10 Center Drive,
MSC 1600, Bethesda, Maryland 20892-1600.**

NIH is an Equal Opportunity Employer

CONSULTANTS AND OTHER LEVELS NEEDED IN ALL SPECIALITIES OF PSYCHIATRY

Consultants require Section 12 or 20

Immediate Start

Short Term/Long Term
Assignments

Great on-call

£ £ Excellent £ £
£ £ Rates of £ £
£ £ Pay £ £



THROUGHOUT THE UK

Accommodation
Provided


Work Permits
Arranged

Contributions to
Travelling Expenses

Call Anna: Tel. 01703 393988; Fax. 01703 393908; Email anna@direct-medical.com

DIRECT
MEDICAL SERVICES

“Earn, don't Burn this Summer”



Locum Psychiatrists – Amongst the best rates in the UK

Have you ever thought that you are worth more money than you're being paid? That your skills, commitment and flexibility deserve more recognition? Here at PRN we agree, which is why we are offering what we believe to be the highest rates of pay in the UK.

A National Contract Holder and one of the leading suppliers of Psychiatrists to Trusts and Hospitals throughout the UK, PRN can also offer an incredibly wide range of challenging and rewarding roles. Our staff team (all of whom are experienced in their own right and therefore know the business from both sides) can find the ideal position to match your skills and requirements.

“My advice to you is to contact PRN immediately.”

Call 0181 558 9466 or National Number 0870 840 0999



Alternatively fax your details to
0181 558 2682 or e-mail:
PRNRecruitment@compuserve.com

— PRN —
RECRUITMENT

BUFS2293



Spot the Edronax difference.



 Highly selective noradrenaline re-uptake inhibitor (NARI)¹

 **dronax**[®]
reboxetine tablets 

Helps restore energy and motivation in tired depressed patients^{2,3}

EDRONAX[®] ABBREVIATED PRESCRIBING INFORMATION


Presentation: Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Posology and method of administration:** **Adults** 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. **Elderly and children** Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children, and therefore reboxetine cannot be recommended in either of these groups. **Renal/Hepatic Insufficiency** 2 mg b.i.d.

precautions for use: Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO-inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering the drug to elderly patients with low blood pressure. **Interactions with other medicaments and other forms of**

that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating, tachycardia, vertigo, urinary hesitancy

NHS Price: Pack of 60 tablets in blisters £19.80. **Legal Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH, UK. **Marketing Authorisation Number:** PL 0032/0216 **References:** 1. Brunello N et al. *Human Psychopharmacology* 1998;13:S13-S19. 2. Dubini A et al. *J Psychopharmacol* 1997; 11(4):S17-S23. 3. Montgomery SA. *Prescriber* April 1998; 116-119. Further information is available from the Marketing Authorisation Holder: Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton Keynes, MK5 8PH, UK. Telephone: 01908 661101. © Edronax is a registered trademark. Code No.P4008/12/98. Date of preparation:

<https://www.edronax.com>



Prescription for depression,
tender
loving care
and

SEROXAT
PAROXETINE

Now indicated for Social Phobia

Rebuilding the lives
of more anxious
depressed patients than any
other antidepressant¹

PRESCRIBING INFORMATION

Prescribing information

Presentation: 'Seroxat' Tablets, PL 10592/0001-2, each containing either 20 or 30 mg paroxetine as the hydrochloride. 30 (OP) 20 mg tablets, £20.77; 30 (OP) 30 mg tablets, £31.16.

'Seroxat' Liquid, PL 10592/0092, containing 20 mg paroxetine as the hydrochloride per 10 ml. 150 ml (OP), £20.77.

Indications: Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Following satisfactory response, continuation is effective in preventing relapse. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. Treatment of symptoms of social anxiety disorder/social phobia.

Dosage: Adults: Depression: 20 mg a day. Review response within two to three weeks and if necessary increase dose in 10 mg increments to a maximum of 50 mg according to response.

Obsessive compulsive disorder: 40 mg a day. Patients should be given 20 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 60 mg a day.

Panic disorder: 40 mg a day. Patients should be given 10 mg a day initially and the dose increased weekly in 10 mg increments.

Some patients may benefit from a maximum dose of 50 mg a day.

Social anxiety disorder/social phobia: 20 mg a day. Patients should start on 20 mg and if no improvement after at least two weeks they may benefit from weekly 10 mg dose increases up to a maximum of 50 mg/day according to response. 'Seroxat' has been shown to be effective in 12 week placebo-controlled trials. There is only limited evidence of efficacy after 12 weeks' treatment.

Give orally once a day in the morning with food. The tablets should not be chewed. Continue treatment for a sufficient period, which should be at least four to six months after recovery for depression and may be longer for OCD and panic disorder. As with many psychoactive medications abrupt discontinuation should be avoided – see **Adverse reactions**.

Elderly: Dosing should commence at the adult starting dose and may be increased in weekly 10 mg increments up to a maximum of 40 mg a day according to response.

Children: Not recommended.

Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment: 20 mg a day. Restrict incremental dosage if required to lower end of range.

Contra-indication: Hypersensitivity to paroxetine.

Precautions: History of mania. Cardiac conditions: caution. Caution in patients with epilepsy; stop treatment if seizures develop. Driving and operating machinery.

Drug interactions: Do not use with or within two weeks after MAO inhibitors; leave a two-week gap before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Use lower doses if given with drug metabolising enzyme inhibitors; adjust dosage if necessary with drug metabolising enzyme inducers. Alcohol is not advised. Use lithium with caution and monitor lithium levels. Increased adverse effects with phenytoin; similar possibility with other anticonvulsants.

Pregnancy and lactation: Use only if potential benefit outweighs possible risk.

Adverse reactions: In controlled trials most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (including impotence and ejaculation disorders), dizziness, constipation and decreased appetite.

Also spontaneous reports of dizziness, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash including urticaria with pruritus or angioedema, and symptoms suggestive of postural hypotension. Extrapyramidal reactions reported infrequently; usually reversible abnormalities of liver function tests and hyponatraemia described rarely. Symptoms including dizziness, sensory disturbance, anxiety, sleep disturbances, agitation, tremor, nausea, sweating and confusion have been reported following abrupt discontinuation of 'Seroxat'. It is recommended that when antidepressant treatment is no longer required, gradual discontinuation by dose-tapering or alternate day dosing be considered.

Overdosage: Margin of safety from available data is wide. Symptoms include nausea, vomiting, tremor, dilated pupils, dry mouth, irritability, sweating and somnolence. No specific antidote. General treatment as for overdosage with any antidepressant. Early use of activated charcoal suggested.

Legal category: POM. 10.9.98

SKB **SmithKline Beecham**
Pharmaceuticals




Welwyn Garden City, Hertfordshire AL7 1EY.

'Seroxat' is a trade mark.

© 1998 SmithKline Beecham Pharmaceuticals.

Reference: 1. Data on file.

0998/ST/AD/8/0396J



MISSION: To make depressed patients well again.¹

MEANS: The SNRI that achieves remission rates nearly twice as high as fluoxetine.²

EFEXOR XL: Mission accomplished

REMISSION
ACCOMPLISHED

EFEXOR XL
VENLAFAXINE 75 mg o.d.

Simply effective


AGENT OF REMISSION IN DEPRESSION

EFEXOR[®] XL venlafaxine – PRESCRIBING INFORMATION

Presentation: Capsules containing 75mg or 150mg venlafaxine (as hydrochloride) in an extended release formulation. **Use:** Treatment of depressive illness. **Dosage:** Adults (including the elderly): Usually 75mg, given once daily with food, increasing to 150mg once daily if necessary. The dose can be increased further to 225mg once a day. Dose increments should be made at intervals of approximately 2 weeks or more, but not less than 4 days. Discontinue gradually to reduce the possibility of withdrawal reactions. **Children:** Contraindicated below 18 years of age. **Moderate renal or moderate hepatic impairment:** Doses should be reduced by 50%. Not recommended in severe renal or severe hepatic impairment. **Contra-indications:** Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or any of the excipients present in the product. **Precautions:** **Warn:** Use with caution in patients with myocardial infarction

or a history of epilepsy (discontinue in event of seizure). Patients should not drive or operate machinery if their ability to do so is impaired. Possibility of postural hypotension (especially in the elderly). Women of child-bearing potential should use contraception. Prescribe smallest quantity of tablets according to good patient management. Monitor blood pressure with doses >200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Patients with a history of drug abuse should be monitored carefully. **Interactions:** MAOIs: do not use Efexor XL in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor XL before starting an MAOI. Use with caution in elderly or hepatically-impaired patients taking cimetidine, in patients taking other CNS-active drugs, and in patients taking drugs which inhibit both CYP2D6 and CYP3A4 hepatic enzymes. **Side effects:** Nausea, insomnia,

nervousness, asthenia, abnormal ejaculation/orgasm, anorexia, abnormal vision/accommodation, impotence, vomiting, tremor, abnormal dreams, vasodilatation, hypertension, rash, agitation, hypertonia, paraesthesia, postural hypotension, reversible increases in liver enzymes, slight increase in serum cholesterol, weight gain or loss, hyponatraemia. Symptoms reported on discontinuation of venlafaxine were mostly non-serious and self-limiting and included dizziness, insomnia, nausea and nervousness. **Basic NHS price:** 75mg capsule (PL 00011/0223) – blister pack of 28 capsules; £23.97. 150 mg capsule (PL 00011/0224) – blister pack of 28 capsules; £39.97. **Legal category:** POM. Further information is available upon request from the Product Licence holder: Wyeth Laboratories, Taplow, Maidenhead, Berkshire, SL6 0PH. **References:** 1. Ferrer N. Presentation at Wyeth Symposium, CINP, Glasgow, July 1998. 2. Rickels P. et al. Poster presented at ECNP, Vienna, 1997. Date



What do you need
to bring her back?

Prescribing Information - Solian 200 and Solian 50 Presentation: Solian 200 tablets contain 200mg amisulpride and Solian 50 tablets contain 50mg amisulpride. **Indication:** Acute and chronic schizophrenia including predominant negative symptoms. **Dosage:** Acute psychotic episodes: 400-800mg/day, increasing up to 1200mg/day according to individual response (dose titration not required), in divided doses. Predominantly negative symptoms: 50-300mg once daily adjusted according to individual response. Elderly: administer with caution due to the risk of hypotension or sedation. Renal insufficiency: reduce dose and consider intermittent therapy. Hepatic insufficiency: no dosage adjustment necessary. **Children:** amisulpride is not recommended in children under 15 years (safety not established). **Contraindications:** Hypersensitivity; concomitant prolactin-dependent tumours e.g. pituitary tumours.

occur (discontinue Solian). Caution in patients with a history of epilepsy and Parkinson's disease. **Interactions:** Caution in concomitant administration of CNS depressants (including alcohol), antihypertensives and other hypotensive medications, and dopamine agonists. **Side Effects:** Insomnia, anxiety, agitation. Less commonly somnolence and GI disorders. In common with other neuroleptics Solian causes a reversible increase in plasma prolactin levels. Solian may also cause weight gain, acute dystonia, extrapyramidal symptoms, tardive dyskinesia, hypotension and bradycardia. Rarely, allergic reactions, seizures and neuroleptic malignant syndrome have been reported. **Basic NHS Cost:** Blister packs of: 200mg x 60 tablets - £60.00; 200mg x 90 tablets - £90.00; 50mg x 60 tablets - £16.45; 50mg x 90 tablets - £24.68.

She's frightened, disturbed, disoriented - even disruptive. But behind her screams and tears, she's crying out to you - to bring her back from her terror of acute phase schizophrenia.

A rapid response

You can rely on Solian (amisulpride) in this critical acute phase. A significantly greater number of patients responded to Solian 800mg than haloperidol 20mg (62% vs 44% $p = 0.014$)¹ and Solian controls key symptoms - activation, thought disturbance and hostility - just as effectively.²

You can rely on Solian to start working quickly - with over 50% more patients responding to Solian therapy than to haloperidol within the first 2 weeks.³

Finally, because Solian is an atypical, it won't just bring her back - it'll keep her back in the community. So you can rely on it, just as your patients rely on you.

 **Solian**[®]
AMISULPRIDE



RELIABLE CONTROL OF ACUTE PHASE SCHIZOPHRENIA

Pharmacopsychiatry 1990; 23: 125 - 130. 3.
Tujanski S. *et al.* Presented at ECNP Congress,
Paris, France, 1998, November.

Further information is available on request.
Lorex Synthelabo UK & Ireland Ltd, Foundation
Park, Roxborough Way, Maidenhead, Berks,
SL6 3UD.

http://www.cambridge.org/9780521440000 Published online by Cambridge University Press
Date of preparation: April 1999

Every day he's frustrated and alone.
Every day he wants to be different.
Every day goes by the same.



Many schizophrenia patients are crying out for reassessment. Conventional neuroleptics may have controlled some initial symptoms. However, for many patients, everyday life is still impaired by residual symptoms and side effects. Switching to Risperdal could give them a life worth living.



ONCE DAILY
RisperdalTM
RISPERIDONE

RISPERDAL™ ADDITIONAL INFORMATION
Please refer to Summary of Product Characteristics before prescribing Risperdal (risperidone). **USES:** The treatment of acute and chronic schizophrenia, and other psychotic conditions, in which positive and/or negative symptoms are prominent. Risperdal also alleviates affective symptoms associated with schizophrenia. **DOSEAGE:** Where medically appropriate, gradual discontinuation of previous antipsychotic treatment while Risperdal therapy is initiated is recommended. Where medically appropriate, when switching patients from depot antipsychotics, consider initiating Risperdal therapy in place of the next scheduled injection. The need for continuing existing antiparkinson medication should be re-evaluated periodically. **Adults:** Risperdal may be given once or twice daily. All patients, whether acute or chronic, should start with 2 mg/day. This should be increased to 4 mg/day on the second day and 6 mg/day on the third day. However, some patients such as first-episode psychotic patients may benefit from a slower rate of titration. From then on the dosage can be maintained unchanged, or further individualised if needed. The usual effective dosage is 4 to 8 mg/day although in some patients an optimal response may be obtained at lower doses. Doses above 10 mg/day may increase the risk of extrapyramidal symptoms and should only be used if the benefit is considered to outweigh the risk. Doses above 16 mg/day should not be used. **Elderly, renal and liver disease:** A starting dose of 0.5 mg bd is recommended. This can be individually adjusted with 0.5 mg bd increments to 1 to 2 mg bd. Risperdal is well tolerated by the elderly. Use with caution in patients with renal and liver disease. Not recommended in children aged less than 15 years. **CONTRA-INDICATIONS, WARNINGS, ETC. - Contra-indications:** Known hypersensitivity to Risperdal. **Precautions:** Orthostatic hypotension can occur (alpha-blocking effect). Use with caution in patients with known cardiovascular disease. Consider dose reduction if hypotension occurs. For further sedation, give an additional drug (such as a benzodiazepine) rather than increasing the dose of Risperdal. Drugs with dopamine antagonistic properties have been associated with tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotic drugs should be considered. Caution should be exercised when treating patients with Parkinson's disease or epilepsy. Patients should be advised of the potential for weight gain. Risperdal may interfere with activities requiring mental alertness. Patients should be advised not to drive or operate machinery until their individual susceptibility is known. **Pregnancy and lactation:** Use during pregnancy only if the benefits outweigh the risks. Women receiving Risperdal should not breast feed. **Interactions:** Use with caution in combination with other centrally acting drugs. Risperdal may antagonise the effect of levodopa and other dopamine agonists. On initiation of carbamazepine or other hepatic enzyme-inducing drugs, the dosage of Risperdal should be re-evaluated and increased if necessary. On discontinuation of such drugs, the dosage of Risperdal should be re-evaluated and decreased if necessary. **Side effects:** Risperdal is generally well tolerated and in many instances it has been difficult to differentiate adverse events from symptoms of the underlying disease. Common adverse events include: insomnia, agitation, anxiety, headache. Less common adverse events include: somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. The incidence and severity of extrapyramidal symptoms are significantly less than with haloperidol. However, the following may occur: tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia. If acute, these symptoms are usually mild and reversible upon dose reduction and/or administration of antiparkinson medication. Rare cases of Neuroleptic Malignant Syndrome have been reported. In such an event, all antipsychotic drugs should be discontinued. Occasionally, orthostatic dizziness, hypotension (including orthostatic), tachycardia (including reflex) and hypertension have been observed. An increase in plasma prolactin concentration can occur which may be associated with galactorrhoea, gynaecomastia and disturbances of the menstrual cycle. Oedema and increased hepatic enzyme levels have been observed. A mild fall in neutrophil and/or thrombocyte count has been reported. Rare cases of water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures have been reported. **Overdosage:** Reported signs and symptoms include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. A prolonged QT interval was reported in a patient with concomitant hypokalaemia who had ingested 360mg. Establish and maintain a clear airway, and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal plus a laxative should be considered. Commence cardiovascular monitoring immediately, including continuous electrocardiographic monitoring to detect possible arrhythmias. There is no specific antidote, so institute appropriate supportive measures. Treat hypotension and circulatory collapse with appropriate measures. In case of severe extrapyramidal symptoms, give anticholinergic medication. Continue close medical supervision and monitoring until the patient recovers. **PHARMACEUTICAL PRECAUTIONS:** Tablets: Store below 30°C. Liquid: Store below 30°C; protect from freezing. **LEGAL CATEGORY:** POM. **PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS:** White, oblong tablets containing 1 mg risperidone in packs of 20. PL 0242/0186 £13.45. Pale orange, oblong tablets containing 2 mg risperidone in packs of 60. PL 0242/0187 £79.56. Yellow, oblong tablets containing 3 mg risperidone in packs of 60. PL 0242/0188 £117.00. Green, oblong tablets containing 4 mg risperidone in packs of 60. PL 0242/0189 £154.44. Yellow, circular tablets containing 6 mg risperidone in packs of 28. PL 0242/0317 £109.20. Starter packs containing 6 Risperdal 1 mg tablets are also available £4.15. Clear, colourless solution containing 1 mg risperidone per ml in bottles containing 100 ml. PL 0242/0198 £65.00. **FURTHER INFORMATION IS AVAILABLE FROM THE PRODUCT LICENCE HOLDER, Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ. AP/VER140797**



Date of preparation: August 1998
© Janssen-Cilag Ltd TM trademark



CAMPRAL EC PRESCRIBING INFORMATION

Campral EC acomprasate

Presentation: Off-white round enteric-coated tablets, containing 333mg acomprasate calcium. Printed on one side with 333. **Properties:** Acomprasate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory amino acids, particularly glutamic acid. **Indication:** Maintenance of abstinence in alcohol dependent patients. It should be combined with counselling. **Dosage and Administration:** *Adults ≥ 60kg:* 6 tablets per day (2 tablets taken three times daily with meals) *Adults < 60kg:* 4 tablets per day (2 tablets in the morning, 1 at noon and 1 at night with meals). Recommended treatment period one year, starting as soon as possible after the withdrawal period. Treatment should be maintained if the patient relapses. **Elderly:** Not recommended. **Children:** Not recommended. **Contraindications:** Known hypersensitivity to the drug, renal insufficiency (serum creatinine > 120 micromol/L), severe hepatic failure (Childs-Pugh classification C), pregnancy, lactation. Precautions and

Warnings: Campral EC does not constitute treatment during the withdrawal period. **Interactions:** None observed in studies with diazepam, disulfiram or imipramine. The concomitant intake of alcohol and acomprasate does not affect the pharmacokinetics of either alcohol or acomprasate. **Side Effects:** Diarrhoea, and less frequently nausea, vomiting and abdominal pain; pruritus. These are usually mild and transient. An occasional maculopapular rash and rare cases of bullous skin reactions have been reported. Fluctuations in libido have been reported. Campral EC should not impair the patient's ability to drive or operate machinery. **Overdose:** Gastric lavage; should hypercalcaemia occur, treat patient for acute hypercalcaemia. **Legal Category:** POM. **Pharmaceutical Precautions:** None. **Package Quantities and Basic NHS Price:** 84 blister packed tablets £24.95. **Marketing Authorisation Number/Holder:** 13466/0001, Lipha SA, Lyon, France. **Date of Preparation:** August 1997. Further information is available on request from Merck Pharmaceuticals, Harrier House, High Street, West Drayton, Middlesex, UB7 7QG.



**SPECIAL COMMENDATION
AWARDED 1998
PRIX GALIEN AWARD
FOR INNOVATIVE
PHARMACEUTICAL PRODUCTS**

BRAIN BIOCHEMISTRY ADAPTS TO
LIFE WITH ALCOHOL

CAMPRAL EC HELPS PATIENTS ADAPT TO
LIFE WITHOUT ALCOHOL



Non-aversive **Campral EC** can help reduce the craving in patients who are adapting to a life without alcohol.

EFFECTIVE IN MAINTAINING ABSTINENCE

Campral EC

CLOZARIL

clozapine

CLOZARIL ABBREVIATED PRESCRIBING INFORMATION.

The use of Clozaril is restricted to patients registered with the Clozaril Patient Monitoring Service. **Indication:** Treatment-resistant schizophrenia (patients non-responsive to, or intolerant of, conventional neuroleptics). **Presentations:** 25 mg and 100 mg clozapine tablets. **Dosage and Administration:** Initiation must be in hospital in-patients and is restricted to patients with normal white blood cell and differential counts. Initially, 12.5 mg once or twice on first day, followed by one or two 25 mg tablets on second day. Increase dose slowly, by increments (see data sheet). The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Doses up to 900mg daily may be used. Dose-related convulsions have been reported especially during dose titration. Patients with a history of seizures, those suffering from cardiovascular, renal or hepatic disorders, and the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. **Contra-Indications:** Allergy to any constituents of the formulation. History of drug-induced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause, severe renal or cardiac failure. Active liver disease, progressive liver disease or hepatic failure. **Warning and Precautions:** CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since then strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Because of this risk, CLOZARIL use is limited to treatment-resistant schizophrenic patients:- 1. who have normal leucocyte findings and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least two-weekly for the first year of therapy. After one year's treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue throughout treatment and for four weeks after discontinuation of CLOZARIL. Patients must be under specialist supervision. CLOZARIL supply is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts and a drug supply audit so that CLOZARIL is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact their physician immediately if any kind of infection begins to develop, especially if flu-like. Immediate differential count is necessary if signs or symptoms of infection develop. Re-evaluate any patient developing an infection, or when a routine white blood count of between 3.0 and $3.5 \times 10^9/l$ and/or a neutrophil count between 1.5 and $2.0 \times 10^9/l$, with a view to discontinuing CLOZARIL. If the white blood count falls below $3.0 \times 10^9/l$ and/or the absolute neutrophil count drops below $1.5 \times 10^9/l$, withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Any further fall in white blood/neutrophil count below $1.0 \times 10^9/l$ and/or $0.5 \times 10^9/l$ respectively, after drug withdrawal requires immediate specialised care. Where protective isolation and administration of GM-CSF or G-CSF and broad spectrum antibiotics may be indicated. Discontinue colony stimulating factor when the neutrophil count returns above $1.0 \times 10^9/l$. CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration. Patients, if affected by the sedative action of CLOZARIL, should not drive or operate machinery, administer with caution to patients who participate in activities requiring complete mental alertness. Monitor hepatic function regularly in liver disease. Investigate any signs of liver disease immediately with a view to drug discontinuation. Resume only if LFTs return to normal, then closely monitor patient. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Avoid immobilisation of patients due to increased risk of thromboembolism. Do not give with other drugs with a substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors,

CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, rarely, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant highly protein bound drugs. Clozapine binds to and is partially metabolised by the isoenzymes cytochrome P450 1A2 and P450 2D6. Caution is advised with drugs which possess affinity for these isoenzymes. Concomitant cimetidine and high dose CLOZARIL has been associated with increased plasma clozapine levels and the occurrence of adverse effects. Concomitant fluoxetine and fluvoxamine have been associated with elevated clozapine levels. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. Phenytoin decreases clozapine levels resulting in reduced CLOZARIL effectiveness. No clinically relevant interactions have been noted with tricyclic antidepressants, phenothiazines and type Ic antiarrhythmics, to date. Concomitant lithium or other CNS-active agents may increase the risk of neuroleptic malignant syndrome. The hypertensive effect of adrenaline and its derivatives may be reversed by CLOZARIL. Do not use in pregnant or nursing women. Use adequate contraceptive measures in women of child bearing potential. **Side-Effects:** Neutropenia leading to agranulocytosis (See Warning and Precautions). Rare reports of leucocytosis including eosinophilia. Isolated cases of leukaemia and thrombocytopenia have been reported but there is no evidence to suggest a causal relationship with the drug. Most commonly fatigue, drowsiness, sedation. Dizziness or headache may also occur. CLOZARIL lowers the seizure threshold and may cause EEG changes and delirium. Myoclonic jerks or convulsions may be precipitated in individuals who have epileptogenic potential but no previous history of epilepsy. Rarely it may cause confusion, restlessness, agitation and delirium. Extrapyramidal symptoms are limited mainly to tremor, akathisia and rigidity. Tardive dyskinesia reported very rarely. Neuroleptic malignant syndrome has been reported. Transient autonomic effects e.g. dry mouth, disturbances of accommodation and sweating/temperature regulation. Hypersalivation may occur. Tachycardia and postural hypotension, with or without syncope, and less commonly hypertension may occur. Rarely, profound circulatory collapse has occurred. ECG changes, arrhythmias, pericarditis and myocarditis (with or without eosinophilia) have been reported, some of which have been fatal. Rare reports of thromboembolism. Isolated cases of respiratory depression or arrest, with or without circulatory collapse. Rarely aspiration may occur in patients presenting with dysphagia or as a consequence of acute overdosage. Nausea and vomiting have been reported. Mild constipation may occur, however, it may be more severe and fatal complications including gastrointestinal obstruction and paralytic ileus have occurred. Monitor patients and prescribe laxatives, as required. Care is required in patients receiving other medicines known to cause constipation or with a history of colonic disease or lower abdominal surgery. Asymptomatic elevations in liver enzymes occur commonly and usually resolve without drug discontinuation. Rarely hepatitis and cholestatic jaundice may occur. Very rarely fulminant hepatic necrosis reported. Discontinue CLOZARIL if jaundice develops. Rare cases of acute pancreatitis have been reported. Urinary incontinence and retention and priapism have been reported. Isolated cases of interstitial nephritis have occurred. Benign hyperthermia may occur and isolated reports of skin reactions have been received. Rarely hyperglycaemia has been reported. Rarely increases in CPK values have occurred. With prolonged treatment considerable weight gain has been observed. Sudden unexplained deaths have been reported in patients receiving CLOZARIL. **Package Quantities and Price:** Community pharmacies only: 28 x 25mg tablets: £12.52, (Basic NHS) 28 x 100mg tablets: £50.05 (Basic NHS). Hospital pharmacies only: 84 x 25 mg tablets: £37.54 (Basic NHS), 84 x 100 mg tablets: £150.15 (Basic NHS). Supply of CLOZARIL is restricted to pharmacies registered with the CLOZARIL Patient Monitoring Service. **Product Licence Numbers:** 25 mg tablets: PL 0101/0228, 100 mg tablets: PL 0101/0229. **Legal Category:** POM. CLOZARIL is a registered Trade Mark. **Date of preparation:** January 1999. Full prescribing information, including Summary of Product Characteristics is available from Novartis Pharmaceuticals UK Ltd. Trading as: SANDOZ PHARMACEUTICALS, Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.

THE ENVY

A GOLD STANDARD THERAPY FOR

OF OTHER

TREATMENT-RESISTANT SCHIZOPHRENIA

ATYPICALS?


WHY?

When
others fail,
its
unsurpassed
efficacy
changes
people's
lives.
Why don't
you use
it more?



CLOZARIL
clozapine

A pathway to lasting care
in the community



Short cut from depression



MIRTAZAPINE

ZISPIN[®] 30[▼] mg

There's no time like the present to beat depression

Prescribing Information

Presentation: Blister strips of 28 tablets each containing 30 mg of mirtazapine. **Uses:** Treatment of depressive illness. **Dosage and administration:** The tablets should be taken orally, if necessary with fluid, and swallowed without chewing. **Adults and elderly:** The effective daily dose is usually between 15 and 45 mg. **Children:** Not recommended. The clearance of mirtazapine may be decreased in patients with renal or hepatic insufficiency. Zispin is suitable for once-a-day administration, preferably as a single night-time dose. Treatment should be continued until the patient has been completely symptom-free for 4-6 months. **Contraindications:** Hypersensitivity to mirtazapine or any ingredients of Zispin. **Precautions and warnings:** Reversible white blood cell disorders including agranulocytosis, leukopenia and granulocytopenia have been reported with Zispin. The physician should be alert to symptoms such as fever, sore throat, stomatitis or other signs of infection; if these occur, treatment should be stopped and blood counts checked. **Adverse reactions:** Common: Headache, dizziness, dry mouth, constipation, weight gain, sedation, blurred vision, tachycardia, orthostatic hypotension, increased appetite, dry mouth, fatigue, somnolence, increased sweating, increased salivation, increased tearing, increased lacrimation, increased sweating, increased salivation, increased tearing, increased lacrimation. **Adverse reactions:** The following adverse effects have been reported: **Common:**

melitius. Treatment should be discontinued if jaundice occurs. Moreover, as with other antidepressants, the following should be taken into account: worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; when the depressive phase of manic-depressive psychosis is being treated, it can transform into the manic phase. Zispin has sedative properties and may impair concentration and alertness. **Interactions:** Mirtazapine may potentiate the central nervous dampening action of alcohol; patients should therefore be advised to avoid alcohol during treatment with Zispin. Zispin should not be administered concomitantly with MAO inhibitors or within two weeks of cessation of therapy with these agents; Mirtazapine may potentiate the sedative effects of benzodiazepines; in vitro data suggest that clinically significant interactions are unlikely with mirtazapine. **Pregnancy and lactation:** The safety of Zispin in human pregnancy has not been established. Use during pregnancy is not recommended. **Contraception:** An adequate method of contraception should be employed in nursing mothers is not recommended. **Adverse reactions:** The following adverse effects have been reported: **Common:**

levels. **Rare (<1/1000):** Oedema and accompanying weight gain. Reversible agranulocytosis has been reported as a rare occurrence. (Orthostatic) hypotension, Exanthema, Mania, convulsions, tremor, myoclonus. **Overdosage:** Toxicity studies in animals suggest that clinically relevant cardiotoxic effects will not occur after overdosing with Zispin. Experience in clinical trials and from the market has shown that no serious adverse effects have been associated with Zispin in overdose. Symptoms of acute overdosage are confined to prolonged sedation. Cases of overdose should be treated by gastric lavage with appropriate symptomatic and supportive therapy for vital functions. **Marketing authorization number:** PL 0065/0145 **Legal category:** POM **Basic NHS cost:** £24 for 28 tablets of 30 mg.

For further information, please contact



Nourypharma

Life beyond Alzheimer's.



With new Exelon, you can now help treat the symptoms of people with mild to moderately severe Alzheimer's disease.

While Exelon has not been shown to affect the disease process, six-month trials have established its effectiveness on key areas that Alzheimer's disease attacks - cognition, global functioning and activities of daily living.¹

For carers and family, this could mean some relief from the demands for attention; for the sufferer, it could mean life beyond Alzheimer's.

NEW
EXELON[®]
(rivastigmine)

Beyond cognition: improving functional ability.

EXELON Prescribing Information. **Indication:** Symptomatic treatment of mild to moderately severe Alzheimer's dementia. **Presentation:** Capsules containing 1.5, 3, 4.5 or 6mg rivastigmine. **Dosage and Administration:** Effective dose is 3 to 6mg twice a day. Maintain patients on their highest well-tolerated dose. Maximum dose 6mg twice daily. Reassess patients regularly. Initial dose 1.5mg twice daily, then build up dose, at a minimum of two week intervals, to 3mg twice daily, 4.5mg twice daily then 6mg twice daily, if tolerated well. If adverse effects or weight decrease occur, these may respond to omitting one or more doses. If persistent, daily dose should be temporarily reduced to previous well tolerated dose. **Contraindications:** Known hypersensitivity to rivastigmine or excipients or any other carbamate derivatives; severe liver impairment. **Special Warning & Precautions:** Therapy should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's disease. A caregiver should be available to monitor compliance. There is no experience of use of EXELON in other types of dementia/memory impairment. Nausea and vomiting may occur, particularly when initiating and/or increasing dose. Monitor any weight loss. Use with care in patients with Sick Sinus Syndrome, conduction defects, active gastric or duodenal ulcers, or those predisposed to ulcerative conditions, history of asthma or obstructive pulmonary disease, those predisposed to urinary obstruction and seizures. In renal and mild to moderate hepatic impairment, titrate dose individually. Safety in pregnancy not established; women should not breastfeed. Use in children not recommended. **Interactions:** May exaggerate effects of succinylcholine-type muscle relaxants during anaesthesia. Do not give with cholinomimetic drugs. May interfere with anticholinergic medications. No interactions were observed with digoxin, warfarin, diazepam, or fluoxetine (in healthy volunteers). Metabolic drug interactions unlikely, although it may inhibit butyrylcholinesterase mediated metabolism of other drugs. **Undesirable Effects:** Most commonly (≥5% and twice frequency of placebo): asthenia, anorexia, dizziness, nausea, somnolence,

vomiting. Female patients more susceptible to nausea, vomiting, appetite and weight loss. Other common effects (≥5% and ≥ placebo): abdominal pain, accidental trauma, agitation, confusion, depression, diarrhoea, dyspepsia, headache, insomnia, upper respiratory tract and urinary tract infections. Increased sweating, malaise, weight loss, tremor. Rarely, angina pectoris, gastrointestinal haemorrhage and syncope. No notable abnormalities in laboratory values observed. **Package Quantities and basic NHS Price:** 1.5mg x 28, \$31.50; 1.5mg x 56, \$63.00; 3mg x 28, \$31.50; 3mg x 56, \$63.00; 4.5mg x 28, \$31.50; 4.5mg x 56, \$63.00; 6mg x 28, \$31.50; 6mg x 56, \$63.00. **Legal Classification:** POM. **Marketing Authorisation Number:** 1.5mg, EU/1/98/066/001 - 2; 3mg, EU/1/98/066/004 - 5; 4.5mg, EU/1/98/066/007 - 8; 6mg, EU/1/98/066/010 - 11. Full prescribing information including Summary of Product Characteristics is available from: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.


Reference: 1. Corey-Bloom J, et al. *International Journal of Geriatric Psychopharmacology* 1998; 1: 55-65.

Date of preparation: August 1998.

Code No. EXE 98/63

 NOVARTIS

Years ago he said I do



he still does



everyone has something to say about it

now it's our turn

it's not for
men without
erectile dysfunction
it's not an aphrodisiac
or a fertility pill

rather

it works¹ to restore
natural erectile function
it's easy to take
it's well tolerated²
and it's here

VIAGRATM
sildenafil citrate

ORAL TREATMENT FOR ERECTILE DYSFUNCTION

ABBREVIATED PRESCRIBING INFORMATION
Please refer to the SmPC before prescribing VIAGRA, 25mg, 50mg or 100mg. **Presentation:** Blue film-coated, rounded diamond-shaped tablets containing sildenafil citrate equivalent to 25mg, 50mg and 100mg sildenafil. **Indications:** Erectile dysfunction. Sexual stimulation is required for efficacy. Not for use by women. **Dosage:** **Adults;** 50mg approximately one hour before sexual activity. Adjust dose based on efficacy and toleration. Maximum dose is 100mg. One single dose per day is recommended. If taken with food, the onset of activity may be delayed. **Elderly:** a first dose of 25mg should be used. **Hepatic impairment, severe renal impairment;** 25mg initial dose should be considered; adjust dose based on efficacy and toleration. **Children under 18 years;** Not indicated. **Contra-indications:** Co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form; patients for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders); severe hepatic impairment; hypotension; recent stroke or myocardial infarction; known hereditary degenerative retinal disorders; hypersensitivity to sildenafil or to any of the excipients.

Warnings and precautions: A medical history and physical examination should be undertaken to diagnose erectile dysfunction and determine potential underlying causes. Cardiovascular status, as sexual activity is associated with cardiac risk. Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure and as such potentiates the hypotensive effect of nitrates. Patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease) or predisposed to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia). Patients with bleeding disorders or active peptic ulceration. Not recommended in combination with other treatments for erectile dysfunction. **Drug Interactions:** In combination with inhibitors of CYP3A4 eg ketoconazole, erythromycin, cimetidine, a 25mg starting dose should be considered. Potentiates the hypotensive effects of nitrates (see contra-indications). No potentiation of the increase in bleeding time caused by acetyl salicylic acid (150mg) or the hypotensive effects of alcohol. No data on non-specific phosphodiesterase inhibitors such as theophylline or dipyridamole. **Side-effects:** Clinical

dyspepsia, nasal congestion, altered vision (colour tinge, increased perception of light or blurred vision). Dyspepsia and altered vision more common at 100mg. Muscle aches when sildenafil administered more frequently than recommended. Post marketing experience: priapism. **Driving and operating machinery:** Caution if affected by dizziness or altered vision. **Legal category:** POM. **Basic NHS cost:** Packs of 4, 25mg tablets [EU/1/98/077/002] £16.59; Packs of 8, 25mg tablets [EU/1/98/077/003] £33.19; Packs of 4, 50mg tablets [EU/1/98/077/006] £19.34; Packs of 8, 50mg tablets [EU/1/98/077/007] £38.67; Packs of 4, 100mg tablets [EU/1/98/077/010] £23.50; Packs of 8, 100mg tablets [EU/1/98/077/011] £46.99. **Marketing Authorisation Holder:** Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom. Last revised: 21 October 1998. Further information on request: Pfizer Limited, Sandwich, Kent, CT13 9NJ. **References:** 1. Goldstein I et al. *New Engl J Med*, 1998, 338(20): 1397-1404. 2. Morales A et al. *Int J Impotence Res*, 1998, 10: 69-74. 10312



Royal College of Psychiatrists Annual Meeting

PERCEPTIONS OF DRUG TREATMENT IN AD – ARE WE SPOILT FOR CHOICE?

Topics include:

Cholinesterase inhibitors: the most effective intervention in AD

The pharmacology of cholinesterase inhibitors: ensuring treatment success

Clinical confirmation: cholinesterase inhibitors are not alike

Clinical experience: measuring the effectiveness of treatment

Efficacy and economics mark the end of treatment nihilism in AD

- With the introduction of cholinesterase inhibitors as the most effective treatment for AD to date, the faculty will challenge the perception that these agents are all the same through evaluations of efficacy, safety and differentiating characteristics.
- To determine whether trial data transcribes into everyday clinical practice, the faculty will describe their experience with cholinesterase inhibitors.
- The faculty will present compelling evidence to convince physicians that there is a clear need to improve management of AD. Incorporating pharmacotherapy is urgent and comparable with the management of other diseases of old age but is affordable.

A series of presentations and an opportunity for discussion

Hall 11A, ICC, Birmingham

Thursday 1 July, 1999

19.00–21.00 (including 18.30–19.00 Buffet dinner)

For further information and bookings please contact:

Jo Bowden, Gardiner-Caldwell Communications Ltd, The Towers, Park Lane, Macclesfield, Cheshire SK11 7NG
Tel: 01625 664153. Fax: 01625 664163. e-mail: jo.bowden@gardiner-caldwell.com